General Provisions - The purpose of the work guidelines is to promote institutional, standardized, and scientific management of Zhejiang Chengyi Pharmaceutical Co., Ltd. to ensure the correct and reasonable nature of major business decisions [1] - The guidelines apply to the general manager and other senior management personnel, including vice presidents and financial officers [1] Composition and Appointment Procedures of the General Manager Team - The general manager team consists of one general manager, several vice presidents, and one financial officer [2] - The general manager is nominated by the chairman and appointed or dismissed by the board of directors, while vice presidents and financial officers are nominated by the general manager and appointed or dismissed by the board [2] - The term of the general manager team is three years, with the possibility of reappointment [2] Responsibilities and Duties of the General Manager Team - The general manager is responsible for leading the company's overall work and is accountable to the board of directors [3][12] - The financial officer is responsible for leading the financial management work and ensuring compliance with national accounting regulations [5] - The general manager team must adhere to the company's articles of association and fulfill their duties faithfully to protect the company's interests [6][16] Reporting System - The general manager must report the company's operational status to the board of directors quarterly and must ensure the authenticity of the reports [12][33] - In case of significant incidents or emergencies, the general manager and other senior management must report to the chairman immediately [12][35] Performance Evaluation and Incentive Mechanism - The performance evaluation of the general manager and other senior management is conducted by the board's remuneration and assessment committee [36] - The compensation of the general manager team is linked to the company's performance and individual achievements [37]

宁波美诺华药业股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日以 书面、电子邮件等方式向公司全体董事发出召开第五届董事会第十六次会议的通 知和会议材料。2025 年 8 月 26 日，公司第五届董事会第十六次会议在公司会议 室以现场结合通讯表决方式召开。本次会议由姚成志先生主持，会议应出席董事 集和召开符合《中华人民共和国公司法》等有关法律法规及《公司章程》《董事 会议事规则》的规定。 证券代码：603538 证券简称：美诺华 公告编号：2025-091 转债代码：113618 转债简称：美诺转债 宁波美诺华药业股份有限公司 第五届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 二、董事会会议审议情况 （一）审议通过《2025 年半年度报告及摘要》 具体内容详见公司于上海证券交易所网（www.sse.com.cn）等指定信息披露 媒体同日披露的《2025 年半年度报告》及《2025 年半年度报告摘要》。 本议案已经公司董事会审计委员会全体成员审议通过，并同意 ...

证券代码：603869 证券简称：ST 智知 公告编号：临 2025-028 新智认知数字科技股份有限公司 第五届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 新智认知数字科技股份有限公司（以下简称"公司"）第五届董事会第二十 次会议（以下简称"会议"）通知于 2025 年 8 月 15 日以邮件的形式发出，会议 按照预定时间于 2025 年 8 月 25 日以通讯表决的方式召开。本次会议应到董事 9 名，实际出席董事 9 名，公司全体监事及高级管理人员列席了本次会议。本次会 议由公司董事长史玉江先生主持。本次会议的召开和表决程序符合《中华人民共 和国公司法》等法律、行政法规、规范性文件和《新智认知数字科技股份有限公 司章程》的有关规定，会议决议合法有效。 经与会董事充分讨论，会议审议并通过了如下议案： 一、审议通过了《新智认知 2025 年半年度报告》及摘要。 该议案在提交董事会审议前已经公司第五届董事会审计委员会 2025 年第四 次会议审议通过。具体内容详见同日披露于上海证券交易所网站的《新 ...

证券代码：605158 证券简称：华达新材 公告编号：2025-029 浙江华达新型材料股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 浙江华达新型材料股份有限公司（以下简称"公司"）第四届董事会第七次 会议通知和调整会议时间的通知分别于 2025 年 8 月 18 日、2025 年 8 月 24 日， 以电子邮件及通讯方式送达全体董事，会议于 2025 年 8 月 26 日在公司会议室， 以现场会议的方式召开。本次会议应出席董事 7 人，实际出席董事 7 人，公司监 事和高级管理人员列席本次会议。本次会议由董事长邵明祥先生主持。本次会议 符合《公司法》《公司章程》和《董事会议事规则》的有关规定，会议的召集、 召开合法有效。 二、董事会会议审议情况 （一）审议通过《关于<2025 年半年度报告全文及摘要>的议案》 公司按照相关规定编制了《2025 年半年度报告》及摘要。 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公 司指定 ...

Group 1 - The board of directors of Shanghai RunDa Medical Technology Co., Ltd. held its 24th meeting on August 26, 2025, with all 11 directors present, including independent directors attending via communication [1] - The meeting approved the 2025 semi-annual report and its summary, with a unanimous vote of 11 in favor [2] - A special report on the storage and actual use of raised funds for the first half of 2025 was also approved, reflecting accurate management of the funds [3] Group 2 - The board approved an increase in the estimated amount for daily related party transactions for 2025 due to business development needs, with 9 votes in favor and 2 abstentions [4] - The board decided to cancel the supervisory board and revise the company's articles of association and related systems, transferring the supervisory powers to the audit committee [5] - The board proposed to reappoint Zhonghua Accounting Firm as the financial audit and internal control audit institution for 2025, with unanimous approval [5] - A resolution to convene the first extraordinary general meeting of shareholders in 2025 was also passed, with all directors voting in favor [6]

证券代码：600360 证券简称：*ST 华微 公告编号：2024-069 吉林华微电子股份有限公司 第九届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 吉林华微电子股份有限公司（以下简称"公司"）第九届监事会第六次会议于 2025 年 8 月 26 日在公司本部会议室召开，应到监事 3 名，实到 3 名，符合《公司章程》 规定的法定人数，公司高级管理人员列席了会议。会议通知于 2025 年 8 月 21 日分 别以送达、发送电子邮件及电话通知的方式通知了各位监事，本次会议的通知和召 开符合《公司法》与《公司章程》的规定。会议由监事会召集人禹彤女士主持。经 与会监事审议，通过了如下议案： 一、审议《吉林华微电子股份有限公司 2025 年半年度报告全文及其摘要的议案》 表决结果：同意 3 票；反对 0 票；弃权 0 票。 公司监事会对公司董事会编制的 2025 年半年度报告审核意见如下： 内部管理制度的各项规定； 定，所包含的信息能从各个方面真实地反映出公司 2025 年上半年的经营管理和财务 状况； ...

Core Points - The document outlines the code of conduct for the board of directors and senior management of Ningbo Meinuo Pharmaceutical Co., Ltd, aiming to standardize behavior and enhance corporate governance [1][2][3] Group 1: General Principles - The code is established to ensure compliance with laws, regulations, and the company's articles of association, emphasizing the importance of loyalty and diligence in fulfilling duties [1] - Directors and senior management are required to protect the interests of the company and all shareholders, maintain confidentiality, and avoid conflicts of interest [1][2] Group 2: Duties of Directors and Senior Management - Directors must treat all shareholders fairly, safeguard company assets, and not exploit their positions for personal gain [2][3] - They are obligated to attend board meetings personally or appoint a trusted representative with clear instructions, ensuring accountability [4][5] Group 3: Independent Directors - Independent directors must act independently and fairly, focusing on protecting the interests of minority shareholders and ensuring compliance with regulations [2][3] Group 4: Decision-Making and Reporting - Directors are required to thoroughly review materials before making decisions, ensuring that they understand the implications and risks involved [3][4] - They must report any significant changes or risks that could affect the implementation of board resolutions [5][6] Group 5: Financial Responsibilities - The financial officer is directly responsible for the preparation and disclosure of financial reports, ensuring the company's financial independence and integrity [7][8] - Any irregularities or potential violations must be reported to the board promptly [8][9] Group 6: Appointment and Resignation of Directors - Directors are elected for a term not exceeding three years and can be re-elected, with specific conditions under which they may be disqualified from serving [10][11] - Resignation procedures are outlined, ensuring that the board maintains its required composition [12][13]

浙江海德曼智能装备股份有限公司 审计委员会工作细则 浙江海德曼智能装备股份有限公司 董事会审计委员会工作细则 第一章 总则 第一条、为完善浙江海德曼智能装备股份有限公司（以下简称"公司"）法 人治理结构，促进公司自身规范高效地运作，最大限度地规避财务和经营风险， 确保董事会对经理层的有效监督，根据《上市公司治理准则》等有关法律、法规、 规范性文件和公司章程的规定，公司特设立董事会审计委员会，并制定本工作细 则。 第二条、审计委员会是设在董事会下的一个专门委员会，经董事会批准后成 立。 第三条、审计委员会必须遵守公司章程，在董事会授权的范围内独立行使职 权，并直接向董事会负责。 第二章 审计委员会的产生与组成 第四条、审计委员会由三名委员组成，设主任委员（召集人）一名。审计委 员会委员应当具备履行审计委员会工作职责的专业知识和经验。审计委员会成员 应当勤勉尽责，切实有效地监督、评估上市公司内外部审计工作，促进公司建立 有效的内部控制并提供真实、准确、完整的财务报告。审计委员会成员应当具备 履行审计委员会工作职责的专业知识和经验。 第五条、审计委员会委员为不在公司担任高级管理人员的董事，其中独立董 事过半数，并由 ...

Group 1 - The board of directors of Suzhou Keda Technology Co., Ltd. held its seventh meeting of the fifth session on August 26, 2025, with all six directors present, confirming the legality and validity of the meeting [1] - The audit committee reviewed the financial content of the 2025 semi-annual report and deemed it to accurately reflect the company's operational results, agreeing to submit the report for board approval [1] - The company has prepared a special report on the use of raised funds in accordance with regulatory requirements, which was also approved unanimously by the board [2] Group 2 - The company plans to submit a proposal for changes in registered capital and business scope to the first extraordinary general meeting of shareholders in 2025, which has also received unanimous approval from the board [3] - The company will hold its first extraordinary general meeting of shareholders on September 16, 2025, as per the board's resolution [4]

Meeting Details - The 16th meeting of the 8th Board of Directors of Ruida Technology Co., Ltd. was held on August 25, 2025, in a hybrid format combining in-person and remote participation [1] - All 9 board members attended the meeting, confirming its legality and effectiveness [1] Resolutions Passed - The board approved the 2025 semi-annual report after thorough review by the Audit and Risk Management Committee [1] - The report and its summary were published on the same day on various platforms including the Giant Tide Information Network [2] Related Announcements - The company announced changes to the general manager and modifications to the Articles of Association, which will be submitted for approval at the upcoming extraordinary shareholders' meeting [3] - The board also approved revisions to the management systems for directors, supervisors, and senior management regarding shareholding and changes [3][5] Additional Governance Updates - The company revised its Insider Information Management System and Investor Relations Management System, with full texts published on the Giant Tide Information Network [5] - Proposals for the appointment of the annual audit firm and the convening of the third extraordinary shareholders' meeting were also announced [6]